Saturated salt/concentrated dextran formulation to treat hemorrhage
US4927806A · kind A · utility
34Cited by
5References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 1987 |
| Grant date | May 22, 1990 |
| Priority date | — |
| Expiry date | Apr 23, 2007 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A highly concentrated solution is provided which is both hyperosmotic and hyperoncotic with respect to blood plasma and has utility in treating patients experiencing or threatening to experience hypodynamic shock. The physiologically acceptable solution comprises a crystalloid to provide a osmolarity in excess of 5000 mOsms and a colloid to provide an oncocity in excess of 200 mm Hg. The solution is easily transported and administered by a single, rapid infusion of about less than about 1 ml/kg of body weight and results in a rapid and sustained normalization of circulatory function.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.